« Back to Record
Gianni, L., Dafni, U., Gelber, R., de Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., Cameron, D. A., Mano, M. S., Pedrini, J. L., Veronesi, A., Mendiola, C., Pluzanska, A., Semiglazov, V., Vrdoljak, E., Eckart, M. J., Shen, Z., Skiadopoulos, G., Procter, M., Pritchard, K., Piccart-Gebhart, M., Bell, R. H., & Herceptin Adjuvant (HERA) Trial Study Team, (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet oncology, 12(3), 236-244. doi:10.1016/S1470-2045(11)70033-X
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/125494



